Results 11 to 20 of about 204,272 (330)

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Frontiers in Pharmacology, 2022
Angiotensin-converting enzyme (ACE), a zinc metalloprotein, is a central component of the renin–angiotensin system (RAS). It degrades bradykinin and other vasoactive peptides.
Wenyue Zheng, Wenyue Zheng, Erkang Tian, Zhen Liu, Changhan Zhou, Pei Yang, Pei Yang, Keyue Tian, Wen Liao, Juan Li, Changyu Ren   +10 more
doaj   +2 more sources

Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors

Molecules, 2020
The angiotensin-converting enzyme (ACE) is a two-domain dipeptidylcarboxypeptidase, which has a direct involvement in the control of blood pressure by performing the hydrolysis of angiotensin I to produce angiotensin II.
Julio Caballero
doaj   +2 more sources

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Circulation Research, 2020
Supplemental Digital Content is available in the text. Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in ...
Peng Zhang, Lihua Zhu, Jingjing Cai, Fang Lei, Juan-Juan Qin, Jing Xie, Ye Liu, Yan-Ci Zhao, Xuewei Huang, Lijin Lin, Meng Xia, Ming-Ming Chen, Xu Cheng, Xiao Zhang, D. Guo, Yuanyuan Peng, Yan‐Xiao Ji, J. Chen, Zhi‐Gang She, Yibin Wang, Qingbo Xu, Renfu Tan, Hai-tao Wang, Jun Lin, Pengcheng Luo, Shouzhi Fu, Hongbing Cai, P. Ye, B. Xiao, W. Mao, Liming Liu, You-qin Yan, Mingyu Liu, Manhua Chen, Xiao-Jing Zhang, Xinghuan Wang, R. Touyz, J. Xia, Bing-Hong Zhang, Xiaodong Huang, Yufeng Yuan, L. Rohit, Peter P. Liu, Hongliang Li   +43 more
semanticscholar   +1 more source

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Journal of Travel Medicine, 2020
Highlight Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary ...
J. Diaz
semanticscholar   +1 more source

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).

JAMA cardiology, 2020
Importance The role of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in the setting of the coronavirus disease 2019 (COVID-19) pandemic is hotly debated.
N. Mehta, A. Kalra, A. Nowacki, Scott Anjewierden, Zheyi Han, Pavan Bhat, A. Carmona-Rubio, M. Jacob, G. Procop, S. Harrington, A. Milinovich, L. Svensson, L. Jehi, James B. Young, M. Chung   +14 more
semanticscholar   +1 more source

Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
recent study confirmed that respiratory syndrome uses severe acute respiratory syndrome coronavirus (SARS- CoV) angiotensin- converting enzyme 2 (ACE2) for ...
Junyi Guo, Zheng Huang, Li Lin, Jiagao Lv   +3 more
semanticscholar   +1 more source

Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust

European Journal of Heart Failure, 2020
The SARS‐CoV‐2 virus binds to the angiotensin‐converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients ...
D. Bean, Zeljko Kraljevic, Thomas Searle, R. Bendayan, O'Gallagher Kevin, A. Pickles, A. Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, R. Zakeri, A. Shah, J. Teo, R. Dobson   +13 more
semanticscholar   +1 more source

Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension

Journal of the Renin-Angiotensin-Aldosterone System, 2023
Hypertension is a major risk factor for heart attack, produce atherosclerosis (hardening of the arteries), congestive heart failure, stroke, kidney infection, blindness, end-stage renal infection, and cardiovascular diseases. Many mechanisms are involved
Hafiz Ahmad, Huma Khan, S. Haque, Shameem Ahmad, N. Srivastava, Azhar Khan   +5 more
semanticscholar   +1 more source

Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension

HYPERTENSION, 2020
With the capability of inducing elevated expression of ACE2 (angiotensin-converting enzyme 2), the cellular receptor for severe acute respiratory syndrome coronavirus 2, angiotensin II receptor blockers (ARBs) or ACE inhibitors treatment may have a ...
Guang Yang, Zihu Tan, Ling Zhou, Min Yang, Lang Peng, Jinjin Liu, Jingling Cai, Ru Yang, Junyan Han, Yafei Huang, Shaobin He   +10 more
semanticscholar   +1 more source

Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
report from 138 hospitalized COVID- 19 patients, 31% had hypertension, 10% had diabetes mellitus, and 14.5% had cardiovascular disease, being the 3 most common comorbidities. 11 In the latter study, 36 of the 138 patients needed intensive care unit stays,
R. Sommerstein, M. Kochen, F. Messerli, C. Gräni   +3 more
semanticscholar   +1 more source